If you or your child has tested positive for type 1 diabetes related autoantibodies, we're here for you.
The next step is to get tested again for autoantibodies through the TrialNet Pathway to Prevention risk screening study. This study can identify up to five autoantibodies. JDRF, ADA, and Endocrine Society now classify having two or more of these autoantibodies as early stage type 1 diabetes (T1D).
Participating in the Pathway to Prevention risk screening study is the first step for all TrialNet prevention studies. TrialNet's prevention studies are aiming to slow or stop the disease in individuals who are in early stage T1D.
You qualify for free TrialNet risk screening if you:
- Are between the ages of 2.5 and 45 years and have tested positive for at least one type 1 diabetes related autoantibody outside of TrialNet
- Have not been diagnosed with diabetes
- If you have a family member with type 1 diabetes click here
T1D risk screening will detect if you are in the early stages of T1D. Nearly all people that test positive for two or more diabetes-related autoantibodies will develop the disease.